Novartis New Organizational Model

We continue to be confident in our outlook Medium-term growth driven by 6 key brands with multi-billion dollar outlook CosentyxⓇ, EntrestoⓇ, KesimptaⓇ, KisqaliⓇ, ZolgensmaⓇ, LeqvioⓇ Recently launched ScemblixⓇ and Pluvicto™ Breadth of pipeline 20+ assets with USD ≥1bn potential, Illustrative Group sales USD billion, cc Without any pipeline contribution ~+1.5% CAGR CC ~+5% CAGR CC if Entresto LoE beyond 20262 +4% CAGR CC -9 Cosentyx® Leqvio® Lu-PSMA-617 ScemblixⓇ Other pipeline TasignaⓇ LucentisⓇ which could be approved by 2026 Pipeline quality 85% of pipeline first-in-class/first-in-indication XolairⓇ SandostatinⓇ GilenyaⓇ KesimptaⓇ Kisqali® ZolgensmⓇ Piqray® Sandoz Afinitor® EntrestoⓇ 2020 Future Gx impact up to 20261 IM Core Margin 35% In-market growth drivers / Base business IM Division pipeline probabilized 2026 IM Core Margin High 30s Excludes potential impact from US healthcare reform. Compared to R&D Day 2021, removed Ligelizumab in CSU 1. Estimated based on relevant patents; further extensions possible. Additional products include Promacta, Q-Family and Votrient 2. For internal forecasting purposes we do not expect Gx in US at least until 2025. Constant currencies (cc) and core results are non-IFRS measures. An explanation of our non-IFRS measures can be found in our Condensed Financial Report for Q4 and FY 2021, published February 2, 2022. We have not provided a reconciliation for CAGR CC IM core margin in future periods because we cannot, without unreasonable effort, predict the amounts and timing of events affecting the items we exclude from such measures. 5 NOVARTIS NEW ORGANIZATIONAL MODEL | APRIL 04, 2022 | NOVARTIS INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation